- LakeShore Biopharma (LSB, Financial) launches novel packaging for YSJA™ rabies vaccine in China.
- New packaging approved for market on April 15, 2025, features needle-free reconstitution technology.
- Nationwide distribution set to begin within weeks, enhancing safety and convenience in vaccine administration.
LakeShore Biopharma (LSB) has introduced an innovative packaging solution for its YSJA™ rabies vaccine (Vero Cell) following regulatory approval received on April 15, 2025. The new packaging employs needle-free reconstitution technology aimed at enhancing safety in vaccine administration.
This advanced packaging incorporates specialized components for automatic clamping, needle-free reconstitution, and new needle injection, which significantly improve the convenience and safety of vaccination. Key benefits include a reduction in the risk of compounding contamination, lower occupational exposure for medical staff, decreased needle tip pain, and minimized particle pollution and inflammation risk.
This launch marks the first commercial application of advanced liquid transfer device technology in China's rabies vaccine market, with a nationwide distribution slated to commence within weeks of the April 18, 2025, launch meeting held in Changsha, Hunan Province. LakeShore Biopharma expects this innovation to address critical safety challenges in vaccine administration and fill an unmet need in the market.
